Di Liu

2.1k citations
45 papers · 1.6k indexed · 1 hit paper · h-index 21
Topics
Nanoplatforms for cancer theranostics (10 papers)Renal Diseases and Glomerulopathies (9 papers)Acute Kidney Injury Research (8 papers)

In The Last Decade

Di Liu

45 papers receiving 1.6k citations

Hit Papers

ROS-responsive nano-drug delivery system combining mitoch...2020202620222024202050100150200250

Peers

Di Liu
Comparison fields: 5 of 119
  • Biomedical Engineering 574
  • Molecular Biology 507
  • Materials Chemistry 339
  • Nephrology 308
  • Biomaterials 279
Replace Gaofeng Shu with:
Gaofeng Shu China
Aimei Li China
Jianglin Tan China
Songling Han China
Hiroshi Arakawa Japan
Ali Jahanian‐Najafabadi Iran
Sumi Kim South Korea
Farhad Rezaee Netherlands
Zhijia Liu China
Huidan Zhang China
Di Liu relative to Gaofeng Shu China Gaofeng Shu's profile →
Citations per field
00.5×1.6×
Gaofeng Shu · 1×
Citations per year

Countries citing papers authored by Di Liu

Since Specialization
Citations

This map shows the geographic impact of Di Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Di Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Di Liu more than expected).

Fields of papers citing papers by Di Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Di Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Di Liu. The network helps show where Di Liu may publish in the future.

Co-authorship network of co-authors of Di Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Di Liu. A scholar is included among the top collaborators of Di Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Di Liu. Di Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 101
2 7
3 3
4 5
5 11
6 4
7 19
8 6
9 9
10 16
11 11
12 122
13 161
14
ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injurybreakdown →
266
15 26
16 43
17 30
18 11
19 9
20 8

About Di Liu

Di Liu is a scholar working on Nephrology, Molecular Medicine and Immunology and Allergy, having authored 45 papers that have together received 1.6k indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (10 papers), Renal Diseases and Glomerulopathies (9 papers) and Acute Kidney Injury Research (8 papers). The work is most often cited by research in Nephrology (308 citations), Biomaterials (279 citations) and Molecular Medicine (77 citations). Di Liu has collaborated with scholars based in China, United Kingdom and Czechia. Frequent co-authors include Yongzhong Du, Jing Qi, Gaofeng Shu, Feiyang Jin, Xiaoling Xu, Xiaoying Ying, Hui Yu, Jiansong Ji, Saiping Jiang and Yan Du. Their work appears in journals such as Nature Communications, Nano Letters and ACS Nano.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026